NYSE: CATX
Perspective Therapeutics, Inc.CIK 0000728387 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Summary not yet generated.
Perspective Therapeutics files routine corporate presentation update
2 material changes detected. Sign up free to read the summary.
Partner
Trade CATX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Perspective Therapeutics holds routine annual meeting, elects six directors for one-year terms
3 material changes detected. Sign up free to read the summary.
Perspective Therapeutics to present interim clinical trial results at ASCO 2026
2 material changes detected. Sign up free to read the summary.
Perspective raises $175M, extends cash runway to late 2027, advances three clinical programs
5 material changes detected. Sign up free to read the summary.
Perspective Therapeutics reports Q1 2026 financial results and business updates
2 material changes detected. Sign up free to read the summary.
Perspective Therapeutics discloses preliminary Q1 2026 cash position in analyst presentation
3 material changes detected. Sign up free to read the summary.
Perspective Therapeutics presents interim Phase 1/2a data for lead cancer drug VMT-α-NET
4 material changes detected. Sign up free to read the summary.
Perspective advances VMT-α-NET to 6.0 mCi dose, raises $175M, extends runway to late 2027
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.